Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Nantkwest Inc    NK

NANTKWEST INC (NK)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/17/2018 09/18/2018 09/19/2018 09/20/2018 09/21/2018 Date
2.91(c) 3.04(c) 3.09(c) 3.34(c) 3.3(c) Last
62 080 141 496 68 586 112 057 239 094 Volume
+0.69% +4.47% +1.64% +8.09% -1.20% Change
More quotes
Financials (USD)
Sales 2018 0,02 M
EBIT 2018 -115 M
Net income 2018 -114 M
Debt 2018 -
Yield 2018 -
Sales 2019 0,02 M
EBIT 2019 -127 M
Net income 2019 -127 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 13 228x
Capi. / Sales2019 13 228x
Capitalization 265 M
More Financials
Company
NantKwest, Inc. engages in the development of immunotherapies with a focus on harnessing the power of the innate immune system.It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases.The firm operates through the following geographical segments: United States;... 
More about the company
Latest news on NANTKWEST INC
08/06NANTKWEST : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
07/05NANTKWEST : Names Sonja Nelson Chief Financial Officer
AQ
07/05NANTKWEST : "Modified Nk-92 Cells for Treating Cancer" in Patent Application App..
AQ
06/28NANTKWEST : Names Sonja Nelson Chief Financial Officer
AQ
06/28NANTKWEST : "Modified Nk-92 Cells for Treating Cancer" in Patent Application App..
AQ
06/19NANTKWEST : Names Sonja Nelson Chief Financial Officer
BU
06/13NANTKWEST, INC. : Change in Directors or Principal Officers, Submission of Matte..
AQ
06/05NANTKWEST : to Present at Jefferies 2018 Global Healthcare Conference
BU
05/07NANTKWEST : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
AQ
04/23NANTKWEST : to Present at Upcoming Science & Medicine Conferences
BU
More news
Sector news : Bio Therapeutic Drugs
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
09/22#Trump says he received 'beautiful #letter' from #NK leader #KimJongUn
3
09/22#Sweden, #Switzerland express willingness to send #nuke inspection team to #N..
3
09/20What to expect after third inter-Korean summit #Korea #summit #NK #US
2
09/20Inter-Korean summit kick-starts stalled nuclear talks #Korea #summit #NK #nuc..
1
09/20Biz leaders glad to have seen NK up close #Business #NK #Korea #summit  
More tweets
Qtime:39
News from SeekingAlpha
06/19NantKwest names Sonja Nelson as CFO 
06/13New finance chief at NantKwest 
04/24BY THE NUMBERS : Healthcare Stocks With Big Cash Distributions 
04/02NantHealth Has Turned A Corner 
03/20Unum Therapeutics Updates Proposed IPO Terms 
Chart NANTKWEST INC
Duration : Period :
Nantkwest Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANTKWEST INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 3,50 $
Spread / Average Target 4,8%
EPS Revisions
Managers
NameTitle
Patrick Soon-Shiong Chairman & Chief Executive Officer
Barry J. Simon President, Director & Chief Administrative Officer
Sonja Nelson Chief Financial Officer
Hans Georg Klingemann Vice President-Research & Development
Steven Gorlin Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
NANTKWEST INC-26.50%265
GILEAD SCIENCES5.40%97 887
VERTEX PHARMACEUTICALS20.17%46 021
REGENERON PHARMACEUTICALS3.81%41 426
NEUROCRINE BIOSCIENCES, INC.54.17%10 822
GENMAB2.04%10 170